Centessa Pharmaceuticals’ (CNTA) Buy Rating Reiterated at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a research note released on Friday morning,Benzinga reports. Chardan Capital currently has a $30.00 price objective on the stock.

Several other equities research analysts have also weighed in on the company. Wells Fargo & Company raised their target price on Centessa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, October 27th. Oppenheimer upped their price target on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Guggenheim raised their price objective on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.70.

Centessa Pharmaceuticals Trading Down 5.3%

CNTA opened at $23.69 on Friday. Centessa Pharmaceuticals has a 52 week low of $9.60 and a 52 week high of $30.58. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. The business has a fifty day simple moving average of $26.23 and a 200-day simple moving average of $21.12. The firm has a market cap of $3.18 billion, a P/E ratio of -12.95 and a beta of 1.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). On average, equities analysts expect that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Insider Activity at Centessa Pharmaceuticals

In other news, CTO Tia L. Bush sold 40,000 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total transaction of $1,040,000.00. Following the completion of the sale, the chief technology officer owned 121,503 shares in the company, valued at approximately $3,159,078. The trade was a 24.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mario Alberto Accardi sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the sale, the insider owned 178,801 shares of the company’s stock, valued at approximately $5,364,030. This represents a 5.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 64,000 shares of company stock valued at $1,674,460. 7.09% of the stock is owned by corporate insiders.

Institutional Trading of Centessa Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Avoro Capital Advisors LLC lifted its stake in shares of Centessa Pharmaceuticals by 116.2% in the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock worth $262,096,000 after acquiring an additional 5,808,080 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in Centessa Pharmaceuticals by 20.8% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock worth $110,415,000 after purchasing an additional 1,449,000 shares during the last quarter. Commodore Capital LP raised its position in shares of Centessa Pharmaceuticals by 39.3% in the 2nd quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock valued at $43,340,000 after purchasing an additional 930,711 shares in the last quarter. TCG Crossover Management LLC boosted its stake in shares of Centessa Pharmaceuticals by 8.5% during the 3rd quarter. TCG Crossover Management LLC now owns 3,136,480 shares of the company’s stock valued at $76,060,000 after buying an additional 245,664 shares during the last quarter. Finally, Franklin Resources Inc. grew its position in shares of Centessa Pharmaceuticals by 0.6% during the third quarter. Franklin Resources Inc. now owns 2,558,414 shares of the company’s stock worth $62,042,000 after buying an additional 14,875 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.